Market News AIOpen the app

PMVP stock news · PMV Pharmaceuticals

Stories about PMV Pharmaceuticals (PMVP) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PMVP

Follow PMV Pharmaceuticals (PMVP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PMVP
Free on the App Store and Google Play, or on the web.
  1. Nov 21, 2026, 9:06 AM ET · Trial

    PMV Pharmaceuticals shared new results from its Phase 2 trial for rezatapopt, showing strong responses in patients with advanced tumors.

    Good for PMVP

    PMV reported a 48% confirmed response rate lasting a median 10.4 months among 65 ovarian cancer patients. The results support its planned 2027 application and strengthen the drug's outlook.

  2. Nov 20, 2026, 4:08 PM ET · Market

    PMV Pharmaceuticals shared new results showing their drug rezatapopt works well for certain cancer patients.

    Good for PMVP

    PMV Pharmaceuticals reported a 48% response rate among 65 ovarian cancer patients, with responses lasting a median 10.4 months. I read this as good news for PMVP.

  3. Oct 5, 2026, 9:08 AM ET · Market

    PMV Pharmaceuticals is changing its leaders, with some directors leaving and new ones being chosen.

    Neutral

    PMV filed a notice about officer or director changes and compensation arrangements, but gave no details. The filing does not change the outlook for PMV.